Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

Home
/
update
/
details

Diamyd Medical Advances Type 1 Diabetes Precision Medicine via Accelerated Approval Pathway

NextEdge Admin

10 Sep 2024

2 min 45 sec

Diamyd Medical is pursuing an accelerated approval pathway in the U.S. for its antigen-specific immunotherapy, Diamyd® (rhGAD65/alum), aimed at preserving endogenous insulin production in patients with Stage 3 Type 1 Diabetes. The decision follows a positive futility analysis and is supported by the FDA's Fast Track designation, granted earlier. Diamyd® targets a specific subgroup of patients with the HLA DR3-DQ2 genotype, comprising approximately 40% of those with Stage 3 Type 1 Diabetes, who have shown a positive response to the therapy in prior trials.

The ongoing Phase 3 trial, DIAGNODE-3, will serve as the foundation for a Biologics License Application (BLA) under the FDA's Accelerated Approval Program. An interim study readout, expected in March 2026, will provide efficacy data from around 170 participants who have completed 15-month assessments and safety data from additional enrollees. The primary endpoint of this analysis will be C-peptide levels, a surrogate marker for endogenous insulin production, which the FDA has recognized as reasonably likely to predict clinical benefit. Following the interim readout, the trial will continue until all patients complete their 24-month assessments. Full enrollment of 330 patients is expected by the end of 2025.

CEO Ulf Hannelius stated, “We are committed to working closely with the FDA to seize this opportunity and make Diamyd® available to patients as quickly as possible.” The FDA’s Accelerated Approval Program allows for faster approval based on surrogate endpoints in cases of serious conditions with unmet medical needs.

Conducted across eight European countries and the U.S., the DIAGNODE-3 trial aims to deliver a potentially disease-modifying therapy for Type 1 Diabetes, focusing on preserving the body's ability to produce insulin and improving long-term patient outcomes.